Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/44192
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorBuendía Rodríguez, Jefferson Antonio-
dc.contributor.authorGuerrero Patiño, Diana-
dc.contributor.authorSánchez Caraballo, Jorge Mario-
dc.date.accessioned2024-12-24T17:46:48Z-
dc.date.available2024-12-24T17:46:48Z-
dc.date.issued2022-
dc.identifier.citationBuendía JA, Guerrero Patiño D, Sánchez Caraballo JM. Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis. BMC Pulm Med. 2022 Jun 28;22(1):257. doi: 10.1186/s12890-022-02027-6.spa
dc.identifier.urihttps://hdl.handle.net/10495/44192-
dc.description.abstractABSTRACT: Introduction: Previous evidence has shown that fractional exhaled nitric oxide (FeNO) and eosinophil count in induced sputum (EO) are cost-effective relative to standard of care in guiding the management of children with persistent asthma. There is some doubt as if there are differences between these two biomarkers in terms of costs and benefits. Clarifying this doubt would allow prioritization of the design of clinical practice guidelines. The study aimed to compare in terms of costs and benefits these biomarkers in patients with asthma between 4 and 18 years of age. Methods: A Markov model was used to estimate the cost-utility of asthma management using FeNO and EO in patients between 4 and 18 years of age. Transition probabilities, cost and utilities were estimated from previously published local studies, while relative risks were obtained from the systematic review of published randomized clinical trials. The analysis was carried out from a societal perspective. Results: The expected annual cost per patient with EO was US $1376 (CI 95% US $1376-US $1377) and for FeNO was US $1934 (CI 95% US $1333-US $1334), with a difference of US $42.3 between these strategies. The Quality-adjusted life years (QALYs) per person estimated with EO was 0.95 (CI 95% 0.951-0.952) and for FeNO was 0.94 (CI 95% 0.930-0.940), with a difference of 0.01 between these strategies. The NMB with EO was US $4902 (CI 95% 4900-4904) and for FeNO was US $4841 (CI 95% 4839-4843). The incremental cost-effectiveness ratio of EO was $3566 per QALY gained regarding FeNO. Conclusion: Our study demonstrates that induced sputum-guided management is a strategy cost-effective over FeNO and standard asthma management in Colombia. This evidence should encourage the adoption of any of these techniques to objectively guide the management of children with asthma in routine clinical practice in low-resource settings.spa
dc.format.extent7 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherBMC (BioMed Central)spa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/co/*
dc.titleFractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysisspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupGrupo de Alergología Clínica y Experimental (GACE)spa
dc.publisher.groupGrupo de Investigación en Farmacología y Toxicologíaspa
dc.identifier.doi10.1186/s12890-022-02027-6-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn1471-2466-
oaire.citationtitleBMC Pulmonary Medicinespa
oaire.citationstartpage1spa
oaire.citationendpage7spa
oaire.citationvolume22spa
oaire.citationissue1spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by/4.0/spa
dc.publisher.placeLondres, Inglaterraspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTspa
dc.type.localArtículo de investigaciónspa
dc.subject.decsAsma-
dc.subject.decsAsthma-
dc.subject.decsBiomarcadores-
dc.subject.decsBiomarkers-
dc.subject.decsEosinófilos-
dc.subject.decsEosinophils-
dc.subject.decsPrueba de Óxido Nítrico Exhalado Fraccionado-
dc.subject.decsFractional Exhaled Nitric Oxide Testing-
dc.subject.decsÓxido Nítrico-
dc.subject.decsNitric Oxide-
dc.subject.decsAnálisis Costo-Beneficio-
dc.subject.decsCost-Benefit Analysis-
dc.subject.decsEsputo-
dc.subject.decsSputum-
dc.description.researchgroupidCOL0059567spa
dc.description.researchgroupidCOL0039902spa
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D001249-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D015415-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D004804-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000089142-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D009569-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D003362-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D013183-
dc.relation.ispartofjournalabbrevBMC Pulm. Med.spa
Aparece en las colecciones: Artículos de Revista en Ciencias Médicas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
BuendiaJefferson_2022_Fractional_Exhaled_Nitric_Oxide.pdfArtículo de investigación1.01 MBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons